Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
One&Day Fresh Eye Drops is an over-the-counter (OTC) preservative-free artificial tear solution developed by Optus Pharmaceuticals (formerly DHP Korea). It is formulated as a fixed-dose combination containing chondroitin sulfate sodium, hypromellose 2910, sodium chloride, and potassium chloride. Chondroitin sulfate sodium acts as a corneal protective agent that stabilizes the tear film and promotes corneal healing, while hypromellose 2910 serves as a lubricant to increase viscosity and prolong retention on the ocular surface. The electrolytes sodium chloride and potassium chloride help maintain the physiological osmolarity of natural tears. One&Day Fresh Eye Drops is indicated for the temporary relief of eye fatigue, dry eye symptoms, contact lens discomfort, and blurred vision.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on One&Day Fresh Eye Drops.